Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies

J Clin Microbiol. 2016 Mar;54(3):771-4. doi: 10.1128/JCM.02969-15. Epub 2015 Dec 23.

Abstract

Galactomannan (GM) testing of urine specimens may provide important advantages, compared to serum testing, such as easy noninvasive sample collection. We evaluated a total of 632 serial urine samples from 71 patients with underlying hematological malignancies and found that the urine GM/creatinine ratio, i.e., (urine GM level × 100)/urine creatinine level, which takes urine dilution into account, reliably detected invasive aspergillosis and may be a promising diagnostic tool for patients with hematological malignancies. (This study has been registered at ClinicalTrials.gov under registration no. NCT01576653.).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspergillosis / diagnosis
  • Aspergillosis / etiology*
  • Aspergillosis / urine*
  • Biomarkers
  • Creatinine / blood
  • Creatinine / urine*
  • Female
  • Galactose / analogs & derivatives
  • Hematologic Neoplasms / complications*
  • Humans
  • Male
  • Mannans / blood
  • Mannans / urine*
  • Middle Aged
  • ROC Curve
  • Reproducibility of Results

Substances

  • Biomarkers
  • Mannans
  • galactomannan
  • Creatinine
  • Galactose

Associated data

  • ClinicalTrials.gov/NCT01576653